ATLASMetagenomi Therapeutics (MGX) earnings date: Nov 10, 2026
Metagenomi Therapeutics (MGX) reports earnings for the quarter ended Sep 30, 2026 on Tue, Nov 10, 2026. Analysts expect EPS of -$0.74.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on MGX
| Last price | $0.72 (-7.6%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.1% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Metagenomi Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Metagenomi Therapeutics reports on Nov 10, 2026. One email the day before, with ATLAS’s read on Metagenomi Therapeutics. You can switch it off at any time.
Alert me before MGX reportsFree to start. Creating an account takes under a minute.
Notify me when Metagenomi Therapeutics reports
Track MGX free Add Metagenomi Therapeutics to a free ATLAS watchlist and see its next report date in one place.
MGX earnings at a glance
| Next report (confirmed) | Tue, Nov 10, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.74 |
| Last report | Aug 10, 2026 · Miss |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | +17.2% |
| Average move around a report | ±4.4% (last 5) |
| Sector | Healthcare · Biotechnology |
Metagenomi Therapeutics earnings history: last 5 reports
Metagenomi Therapeutics last reported on Aug 10, 2026: EPS of -$0.73 against an estimate of -$0.52 (-40.4% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 10, 2026 | -$0.52 | -$0.73 | -40.4% | Miss | -1.6% |
| Jul 1, 2026 | $1.91 | $2.06 | +7.9% | Beat | +5.9% |
| May 11, 2026 | -$0.55 | -$0.61 | -10.9% | Miss | -4.3% |
| Mar 5, 2026 | -$0.61 | -$0.60 | +1.6% | In line | -7.5% |
| Dec 17, 2025 | -$0.36 | $0.10 | +127.8% | Beat | -2.9% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for MGX
See the fair value, the probability range and the earnings history of Metagenomi Therapeutics on its ATLAS page.
Metagenomi Therapeutics (MGX) stock analysisPlans from €3.99 a month.
Metagenomi Therapeutics earnings: frequently asked questions
When does Metagenomi Therapeutics (MGX) report earnings?
Metagenomi Therapeutics is scheduled to report on Tuesday, November 10, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for MGX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.74 per share (USD). Estimates can change before the report.
How often does MGX beat earnings estimates?
Of its last 5 reports with a recorded result, Metagenomi Therapeutics beat the EPS estimate 2 times; the average surprise was +17.2%. Past results do not predict the next one.
How much does MGX move around earnings?
Over its last 5 reports the stock moved an average of 4.4% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Metagenomi Therapeutics beat earnings estimates last quarter?
Metagenomi Therapeutics last reported on Aug 10, 2026: EPS of -$0.73 against an estimate of -$0.52 (-40.4% surprise), a miss.
How much does MGX usually move in a day?
On a normal trading day the ATLAS model puts MGX’s one-day range at about ±4.1%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Tue, Nov 10, 2026
Educational information, not investment advice. Disclaimer